Evidence map›Paper›PMID 31286561›Full record

ArticleNeurourology and urodynamics2019

The impact of frailty on treatment for overactive bladder in older adults.

Anne M Suskind, Casey Kowalik, Kathryn Quanstrom, John Boscardin, Shoujun Zhao, W Stuart Reynolds, Kavita Mishra, Emily Finlayson

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurourology and urodynamics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Health Disparities and Overactive Bladder: Bridging the Gap.Current bladder dysfunction reports · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Anne M SuskindDepartment of Urology, University of California, San Francisco, California.ORCID 0000-0002-8437-3861
Casey KowalikDepartment of Urology, University of Kansas Medical Center, Kansas City, Missouri.
Kathryn QuanstromDepartment of Urology, University of California, San Francisco, California.
John BoscardinDepartment of Biostatistics, Uinversity of California, San Francisco, California.
Shoujun ZhaoDepartment of Urology, University of California, San Francisco, California.
W Stuart ReynoldsDepartment of Urology, Vanderbilt University, Nashville, Tennessee.
Kavita MishraDepartment of Obstetrics and Gynecology, Standford University, California.
Emily FinlaysonDepartment of Surgery, University of California, San Francisco, California.
University of California, San Francisco · USAlliance Bioversity International - CIAT · ITStanford University · USUniversity of Kansas Medical Center · USVanderbilt University · US

Funding

UCSF KURe Career Development ProgramK12DK083021 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BASKIN, LAURENCE, CARROLL, PETER R · 2008 to 2017
$5.9M
NIDDK NIH HHS K12 DK083021
6 · The paper itself

Abstract

aimsTo examine the impact of frailty on treatment outcomes for overactive bladder (OAB) in older adults starting pharmacotherapy, onabotulinumtoxinA, and sacral neuromodulation.

methodsThis is a prospective study of men and women age ≥60 years starting pharmacotherapy, onabotulinumtoxinA, or sacral neuromodulation. Subjects were administered questionnaires at baseline and again at 1- and 3-months. Frailty was assessed at baseline using the timed up and go test (TUGT), whereby a TUGT time of ≥12 seconds was considered to be slow, or frail. Response to treatment was assessed using the overactive bladder symptom score (OABSS) and the OAB-q SF (both Bother and HRQOL subscales). Information on side effects/adverse events was also collected. Mixed effects linear modeling was used to model changes in outcomes over time both within and between groups.

resultsA total of 45 subjects enrolled in the study, 40% (N = 18) of whom had a TUGT ≥12 seconds. Both TUGT groups demonstrated improvement in OAB symptoms over time and there were no statistically significant differences in these responses per group (all P-values >.05). Similar trends were found for both OAB-q SF Bother and OAB-q SF HRQOL questionnaire responses. Side effects and adverse events were not significantly different between groups (all P's >.05).

conclusionsAdults ≥60 years of age starting second- and third-line treatments for OAB, regardless of TUGT time, demonstrated improvement in OAB symptoms at 3 months. These findings suggest that frail older adults may receive comparable benefit and similar rates of side effects compared with less frail older individuals.

Indexed as

Electric Stimulation TherapyAgedBotulinum Toxins, Type AFemaleFrailtyHumansMaleMiddle AgedPostural BalanceProspective StudiesQuality of LifeSurveys and QuestionnairesTreatment OutcomeUrinary Bladder, OveractiveUrological AgentsBotulinum Toxins, Type AUrological Agentsbotoxelderlygeriatricpharmacotherapysacral neuromodulationtimed up and go test

Identifiers

PMID31286561
PMCPMC6706315
OpenAlexW2951522896

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.